JPMorgan analyst Anupam Rama removed Ultragenyx (RARE) from the firm’s Analyst Focus List after the company announced that neither the ORBIT nor the COSMIC studies achieved the primary endpoint of reduction in annualized fracture rate. The analyst is “surprised and disappointed” by the outcome. JPMorgan expects a sentiment overhang on Ultragenyx shares moving forward. The firm keeps an Overweight rating on the name.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Wells cuts Ultragenyx target, not throwing in the towel yet
- Mereo BioPharma downgraded to Hold from Buy at Jefferies
- Ultragenyx price target lowered to $63 from $114 at Jefferies
- Ultragenyx price target lowered to $44 from $50 at Barclays
- Ultragenyx: Refocusing on Apazunersen and Strengthened Balance Sheet Support Buy Rating Despite OI Setback